Anhui Anke Biotechnology Group Co Ltd
SZSE:300009

Watchlist Manager
Anhui Anke Biotechnology Group Co Ltd Logo
Anhui Anke Biotechnology Group Co Ltd
SZSE:300009
Watchlist
Price: 8.75 CNY -1.46% Market Closed
Market Cap: 14.6B CNY
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Anhui Anke Biotechnology Group Co Ltd stock under the Base Case scenario is 14.33 CNY. Compared to the current market price of 8.75 CNY, Anhui Anke Biotechnology Group Co Ltd is Undervalued by 39%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
14.33 CNY
Undervaluation 39%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

5.3
P/S
P/S
Price to Sales
5.3
vs History
85
vs Industry
59
Median 3Y
6.2
Median 5Y
6.9
Industry
7
Forward
5.2
More Details
18.7
P/E
P/E
Price to Earnings
18.7
vs History
82
vs Industry
8
Median 3Y
21.6
Median 5Y
41.5
Industry
21.5
Forward
15.8
More Details
19.6
P/OCF
P/OCF
Price to OCF
19.6
vs History
71
vs Industry
9
Median 3Y
20.3
Median 5Y
23.9
Industry
20
More Details
24.4
P/FCFE
P/FCFE
Price to FCFE
24.4
vs History
79
vs Industry
8
Median 3Y
32.4
Median 5Y
41.4
Industry
25.4
More Details
3.7
P/B
P/B
Price to Book Value
3.7
vs History
90
vs Industry
26
Median 3Y
4.7
Median 5Y
5.2
Industry
2.4
More Details
4.9
EV/S
EV/S
Enterprise Value to Sales
4.9
vs History
85
vs Industry
52
Median 3Y
5.8
Median 5Y
6.5
Industry
7.3
Forward
4.8
More Details
6.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.3
vs History
85
vs Industry
50
Median 3Y
7.5
Median 5Y
8.3
Industry
9.3
More Details
16
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
16
vs History
79
vs Industry
9
Median 3Y
18.1
Median 5Y
31.7
Industry
4
Forward
11.4
More Details
16
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
16
vs History
79
vs Industry
9
Median 3Y
18.1
Median 5Y
31.7
Industry
3.8
Forward
14.2
More Details
18
EV/OCF
EV/OCF
Enterprise Value to OCF
18
vs History
73
vs Industry
10
Median 3Y
18.7
Median 5Y
22.5
Industry
4.9
More Details
22.6
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
22.6
vs History
79
vs Industry
7
Median 3Y
30.7
Median 5Y
39.2
Industry
3.3
More Details
3.8
EV/IC
EV/IC
Enterprise Value to IC
3.8
vs History
87
vs Industry
35
Median 3Y
4.7
Median 5Y
5.4
Industry
4.3
More Details

Multiples Across Competitors

Competitors Multiples
Anhui Anke Biotechnology Group Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Anhui Anke Biotechnology Group Co Ltd
SZSE:300009
14.7B CNY 5.3 18.7 16 16
FR
Pharnext SCA
OTC:PNEXF
6T USD 36 635 005.2 -174 120.7 -211 438.1 -209 025.3
US
Abbvie Inc
NYSE:ABBV
362.4B USD 6.4 85.5 16.8 25.3
US
Amgen Inc
NASDAQ:AMGN
164.8B USD 4.9 40.3 16.3 28.8
US
Gilead Sciences Inc
NASDAQ:GILD
139.9B USD 4.9 291.5 11.4 14.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.6B USD 11.5 -236.4 25.9 27.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 923 -490.7 -534.4 -520.1
AU
CSL Ltd
ASX:CSL
122.4B AUD 5.1 28 17.3 21.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
69.9B USD 4.9 15.8 10.2 11.4
US
Seagen Inc
F:SGT
39.3B EUR 18.5 -56.8 -61.1 -55.1
NL
argenx SE
XBRU:ARGX
33B EUR 16.3 42.9 316.4 -2 330.7
P/S Multiple
Revenue Growth P/S to Growth
CN
Anhui Anke Biotechnology Group Co Ltd
SZSE:300009
Average P/S: 3 330 636.9
5.3
13%
0.4
FR
Pharnext SCA
OTC:PNEXF
36 635 005.2
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.4
8%
0.8
US
Amgen Inc
NASDAQ:AMGN
4.9
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.9
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.5
10%
1.1
US
E
Epizyme Inc
F:EPE
1 923
N/A N/A
AU
CSL Ltd
ASX:CSL
5.1
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.9
7%
0.7
US
S
Seagen Inc
F:SGT
18.5
30%
0.6
NL
argenx SE
XBRU:ARGX
16.3
37%
0.4
P/E Multiple
Earnings Growth PEG
CN
Anhui Anke Biotechnology Group Co Ltd
SZSE:300009
Average P/E: 74.7
18.7
14%
1.3
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -174 120.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
85.5
88%
1
US
Amgen Inc
NASDAQ:AMGN
40.3
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
291.5
185%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -236.4 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -490.7 N/A N/A
AU
CSL Ltd
ASX:CSL
28
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.8
11%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.8 N/A N/A
NL
argenx SE
XBRU:ARGX
42.9
19%
2.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Anhui Anke Biotechnology Group Co Ltd
SZSE:300009
Average EV/EBITDA: 53.8
16
18%
0.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -211 438.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.8
13%
1.3
US
Amgen Inc
NASDAQ:AMGN
16.3
17%
1
US
Gilead Sciences Inc
NASDAQ:GILD
11.4
7%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.9
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -534.4 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.2
14%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.1 N/A N/A
NL
argenx SE
XBRU:ARGX
316.4
166%
1.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Anhui Anke Biotechnology Group Co Ltd
SZSE:300009
Average EV/EBIT: 20.6
16
14%
1.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -209 025.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
25.3
28%
0.9
US
Amgen Inc
NASDAQ:AMGN
28.8
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
14.3
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.1
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -520.1 N/A N/A
AU
CSL Ltd
ASX:CSL
21.6
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.4
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.1 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 330.7 N/A N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 242,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.